130 related articles for article (PubMed ID: 30570881)
1. Hyperthermic intraperitonal chemotherapy is an independent risk factor for development of acute kidney injury.
Dagel T; Misirlioglu S; Tanju S; Afsar B; Selcukbiricik F; Erus S; Vatansever D; Balik E; Taskiran C; Dilege S; Molinas Mandel N; Bugra D; Yalti T; Kanbay M
J BUON; 2018; 23(5):1528-1533. PubMed ID: 30570881
[TBL] [Abstract][Full Text] [Related]
2. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
[TBL] [Abstract][Full Text] [Related]
3. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
[TBL] [Abstract][Full Text] [Related]
4. Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy.
Cheng CC; Yeh HC; Su PW; Ho CL; Chang SC
Int J Hyperthermia; 2024; 41(1):2304250. PubMed ID: 38342495
[TBL] [Abstract][Full Text] [Related]
5. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic intraperitoneal chemotherapy with cisplatin: Amifostine prevents acute severe renal impairment.
Bouhadjari N; Gabato W; Calabrese D; Msika S; Keita H
Eur J Surg Oncol; 2016 Feb; 42(2):219-23. PubMed ID: 26278017
[TBL] [Abstract][Full Text] [Related]
7. Assessment of nephrotoxicity associated with combined cisplatin and mitomycin C usage in laparoscopic hyperthermic intraperitoneal chemotherapy.
Kapoor R; Robinson KA; Cata JP; Owusu-Agyemang P; Soliz JM; Hernandez M; Mansfield P; Badgwell B
Int J Hyperthermia; 2019; 36(1):493-498. PubMed ID: 30935256
[TBL] [Abstract][Full Text] [Related]
8. Eliminating the need for preoperative intravenous hyperhydration: Sodium thiosulfate as nephrotoxicity prevention in HIPEC-treated patients - A retrospective analysis.
Vachez E; Kefleyesus A; Bakrin N; Ranchon F; Rioufol C; Vassal O; Al-Hadeedi O; Kepenekian V; Glehen O
Eur J Surg Oncol; 2024 Feb; 50(2):107955. PubMed ID: 38219699
[TBL] [Abstract][Full Text] [Related]
9. Acute Kidney Injury Following Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.
Chen KL; Shamavonian R; Karpes JB; Alzahrani NA; Morris DL
Anticancer Res; 2021 Mar; 41(3):1641-1646. PubMed ID: 33788760
[TBL] [Abstract][Full Text] [Related]
10. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
11. Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study.
Kurreck A; Gronau F; Alberto Vilchez ME; Abels W; Enghard P; Brandl A; Francis R; Föhre B; Lojewski C; Pratschke J; Thuss-Patience P; Modest D; Rau B; Feldbrügge L
Ann Surg Oncol; 2022 Jan; 29(1):152-162. PubMed ID: 34350529
[TBL] [Abstract][Full Text] [Related]
12. HIPEC-Induced Acute Kidney Injury: A Retrospective Clinical Study and Preclinical Model.
Liesenfeld LF; Wagner B; Hillebrecht HC; Brune M; Eckert C; Klose J; Schmidt T; Büchler MW; Schneider M
Ann Surg Oncol; 2022 Jan; 29(1):139-151. PubMed ID: 34260006
[TBL] [Abstract][Full Text] [Related]
13. Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study.
Cata JP; Zavala AM; Van Meter A; Williams UU; Soliz J; Hernandez M; Owusu-Agyemang P
Int J Hyperthermia; 2018 Aug; 34(5):538-544. PubMed ID: 28812384
[TBL] [Abstract][Full Text] [Related]
14. Acute kidney injury after cytoreductive surgery and hyperthermic intraoperative cisplatin chemotherapy for malignant pleural mesothelioma.
Hod T; Freedberg KJ; Motwani SS; Chen M; Frendl G; Leaf DE; Gupta S; Mothi SS; Richards WG; Bueno R; Waikar SS
J Thorac Cardiovasc Surg; 2021 Apr; 161(4):1510-1518. PubMed ID: 32631662
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
[TBL] [Abstract][Full Text] [Related]
16. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
[TBL] [Abstract][Full Text] [Related]
17. Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with Cisplatin.
Laplace N; Kepenekian V; Friggeri A; Vassal O; Ranchon F; Rioufol C; Gertych W; Villeneuve L; Glehen O; Bakrin N
Int J Hyperthermia; 2020; 37(1):897-902. PubMed ID: 32689832
[TBL] [Abstract][Full Text] [Related]
18. Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study.
D'Hondt V; Goffin F; Roca L; Dresse D; Leroy C; Kerger J; Cordier L; de Forges H; Veys I; Liberale G
Int J Gynecol Cancer; 2016 Jun; 26(5):912-7. PubMed ID: 27051055
[TBL] [Abstract][Full Text] [Related]
19. Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Hakeam HA; Arab A; Azzam A; Alyahya Z; Eldali AM; Amin T
Cancer Chemother Pharmacol; 2018 Apr; 81(4):697-704. PubMed ID: 29429054
[TBL] [Abstract][Full Text] [Related]
20. Anesthetic management and renal function in pediatric patients undergoing cytoreductive surgery with continuous hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin.
Owusu-Agyemang P; Arunkumar R; Green H; Hurst D; Landoski K; Hayes-Jordan A
Ann Surg Oncol; 2012 Aug; 19(8):2652-6. PubMed ID: 22451231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
